📊 GNPX Key Takeaways
Is Genprex, Inc. (GNPX) a Good Investment?
Genprex is a pre-revenue biotech company with $16.2M in annual net losses, negative operating cash flow of $15.3M, and approximately 6 months of cash runway at current burn rates. Without revenue generation, clinical trial milestones, or significant capital raises, the company faces imminent funding pressure and substantial shareholder dilution risk.
Genprex is a pre-revenue biotech with persistent operating losses (~$15.5M) and deeply negative ROE/ROA, indicating no clear path to profitability. Although debt-free with a strong current ratio, its ~$7.8M cash covers less than a year of burn, implying likely near-term financing and dilution. On fundamentals alone, risk outweighs strengths until clinical milestones unlock funding or revenue.
Why Buy Genprex, Inc. Stock? GNPX Key Strengths
- Strong liquidity position with 3.84x current ratio and $7.8M cash reserves
- Zero debt on balance sheet provides financial flexibility
- Recent insider Form 4 filings indicate management engagement
- Debt-free balance sheet with low liabilities and high current ratio
- Cash position sufficient for near-term obligations
- Capex-light model enabling focus on R&D
GNPX Stock Risks: Genprex, Inc. Investment Risks
- Zero revenue with unsustainable -$15.3M annual operating cash burn
- Negative ROE (-203.8%) and ROA (-159.7%) destroying shareholder value
- Less than 6 months of cash runway requires immediate capital raise or operational restructuring
- Pre-revenue biotech status implies unproven clinical efficacy and extended path to commercialization
- High dilution risk from mandatory future equity financing
- Short cash runway versus operating burn, creating high dilution risk
- No revenue and continued operating losses with negative returns on capital
- Clinical/regulatory execution risk delaying commercialization
Key Metrics to Watch
- Cash burn rate and runway remaining
- Clinical trial progress and FDA milestone achievements
- Capital raise announcements and dilution impact
- Operating expense reduction initiatives
- Quarterly operating cash flow and cash runway
- Clinical/approval milestones and partnership or grant funding
Genprex, Inc. (GNPX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.84x current ratio provides a solid financial cushion.
GNPX Profit Margin, ROE & Profitability Analysis
GNPX vs Healthcare Sector: How Genprex, Inc. Compares
How Genprex, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Genprex, Inc. Stock Overvalued? GNPX Valuation Analysis 2026
Based on fundamental analysis, Genprex, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Genprex, Inc. Balance Sheet: GNPX Debt, Cash & Liquidity
GNPX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Genprex, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-266.89 indicates the company is currently unprofitable.
GNPX Revenue Growth, EPS Growth & YoY Performance
GNPX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2022 | N/A | -$3.4M | $-0.07 |
| Q2 2022 | N/A | -$4.0M | $-0.08 |
| Q1 2022 | N/A | -$5.7M | $-0.12 |
| Q3 2021 | N/A | -$2.8M | N/A |
| Q2 2021 | N/A | -$4.0M | N/A |
| Q1 2019 | N/A | -$694.0K | N/A |
| Q3 2018 | N/A | -$715.1K | N/A |
| Q2 2018 | N/A | -$1.2M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Genprex, Inc. Dividends, Buybacks & Capital Allocation
GNPX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Genprex, Inc. (CIK: 0001595248)
📋 Recent SEC Filings
❓ Frequently Asked Questions about GNPX
What is the AI rating for GNPX?
Genprex, Inc. (GNPX) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 82% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are GNPX's key strengths?
Claude: Strong liquidity position with 3.84x current ratio and $7.8M cash reserves. Zero debt on balance sheet provides financial flexibility. ChatGPT: Debt-free balance sheet with low liabilities and high current ratio. Cash position sufficient for near-term obligations.
What are the risks of investing in GNPX?
Claude: Zero revenue with unsustainable -$15.3M annual operating cash burn. Negative ROE (-203.8%) and ROA (-159.7%) destroying shareholder value. ChatGPT: Short cash runway versus operating burn, creating high dilution risk. No revenue and continued operating losses with negative returns on capital.
What is GNPX's revenue and growth?
Genprex, Inc. reported revenue of $0.0.
Does GNPX pay dividends?
Genprex, Inc. does not currently pay dividends.
Where can I find GNPX SEC filings?
Official SEC filings for Genprex, Inc. (CIK: 0001595248) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is GNPX's EPS?
Genprex, Inc. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is GNPX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Genprex, Inc. has a STRONG SELL rating with 82% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is GNPX stock overvalued or undervalued?
Valuation metrics for GNPX: ROE of -203.8% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy GNPX stock in 2026?
Our dual AI analysis gives Genprex, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is GNPX's free cash flow?
Genprex, Inc.'s operating cash flow is $-15.3M, with capital expenditures of $0.0.
How does GNPX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -203.8% (avg: 15%), current ratio 3.84 (avg: 2).